Neoleukin Therapeutics, Inc. (NLTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Neoleukin Therapeutics, Inc. (NLTX) trades at $3.49 with AI Score 52/100 (Grade B). Neoleukin Therapeutics, Inc. is a biopharmaceutical company specializing in the development of immunotherapies using protein design technology. Market cap: $8.20M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for NLTX: NLTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NLTX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NLTX: 3/7 perspectives are bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Neoleukin Therapeutics, Inc. (NLTX) Healthcare & Pipeline Overview
Neoleukin Therapeutics, Inc. pioneers de novo protein therapeutics, focusing on immunotherapies for cancer, inflammation, and autoimmunity. Their lead candidate, NL-201, mimics interleukin cytokines to combat cancers like renal cell carcinoma and melanoma, positioning them in the competitive specialty drug market with innovative protein design technology.
What Is the Investment Thesis for NLTX?
Neoleukin Therapeutics presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's innovative protein design technology and lead candidate, NL-201, offer potential for significant growth in the cancer immunotherapy market. A key value driver is the successful clinical development and regulatory approval of NL-201 for renal cell carcinoma and melanoma. Upcoming clinical trial results will be critical catalysts. However, the company's small market capitalization ($0.01B) and limited resources pose significant risks, particularly regarding funding and competition. The company's future success hinges on positive clinical data and strategic partnerships.
Based on FMP financials and quantitative analysis
NLTX Key Highlights
- Neoleukin Therapeutics focuses on developing immunotherapies using protein design technology.
- The company's lead product candidate, NL-201, targets cancer by mimicking the activity of interleukin cytokines.
- Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, Washington.
- The company changed its name from Aquinox Pharmaceuticals, Inc. in August 2019.
- Neoleukin Therapeutics has a market capitalization of $8.20M and a beta of 1.10.
Who Are NLTX's Competitors?
NLTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NLTX's Key Strengths?
- Innovative protein design technology.
- Lead product candidate targeting significant unmet medical need.
- Experienced management team.
- Focus on a high-growth market segment.
What Are NLTX's Weaknesses?
- Limited financial resources.
- Small number of employees.
- Dependence on a single lead product candidate.
- Early stage of development.
What Could Drive NLTX Stock Higher?
- Clinical trial results for NL-201 in renal cell carcinoma.
- Clinical trial results for NL-201 in melanoma.
- Expansion of NL-201 clinical trials to additional cancer types.
- Potential strategic partnerships and licensing agreements.
What Are the Key Risks for NLTX?
- Financial-distress signal — its Altman Z-Score of -1.35 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-37.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for NL-201.
- Regulatory hurdles in obtaining approval for NL-201.
- Competition from larger pharmaceutical companies with more resources.
- Difficulty in securing funding to support research and development.
What Are the Growth Opportunities for NLTX?
- Expansion of NL-201 Clinical Trials: Neoleukin has the opportunity to expand the clinical trials for NL-201 to include additional cancer types beyond renal cell carcinoma and melanoma. This expansion could significantly increase the potential market size for NL-201. The global market for cancer therapies is projected to reach hundreds of billions by 2030, providing a substantial opportunity for Neoleukin if NL-201 demonstrates broad efficacy. The timeline for this expansion depends on the success of ongoing trials and securing additional funding.
- Strategic Partnerships and Licensing Agreements: Neoleukin can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide Neoleukin with access to additional funding, expertise, and resources. The market for licensing agreements in the biopharmaceutical industry is highly active, with numerous deals occurring annually. Securing a partnership could provide a significant boost to Neoleukin's valuation and future prospects.
- Development of New Immunotherapies: Neoleukin's protein design technology platform allows for the development of new immunotherapies targeting a wide range of diseases beyond cancer, including inflammation and autoimmunity. Expanding its pipeline of product candidates can diversify Neoleukin's revenue streams and reduce its reliance on NL-201. The market for immunotherapies is experiencing rapid growth, driven by advancements in protein engineering and a better understanding of the immune system.
- Advancements in Protein Design Technology: Continued advancements in protein design technology could lead to the development of more effective and targeted immunotherapies. Neoleukin can invest in research and development to improve its protein design platform and create novel proteins with enhanced therapeutic activity. The market for protein engineering technologies is growing rapidly, driven by increasing demand for personalized medicine and targeted therapies.
- Regulatory Approval and Commercialization of NL-201: The successful regulatory approval and commercialization of NL-201 would be a major growth driver for Neoleukin. This would validate the company's protein design technology and establish Neoleukin as a player in the cancer immunotherapy market. The timeline for regulatory approval depends on the results of clinical trials and the review process by regulatory agencies such as the FDA. Commercialization would require significant investment in sales and marketing infrastructure.
What Opportunities Does NLTX Have?
- Expansion of clinical trials to additional cancer types.
- Strategic partnerships and licensing agreements.
- Development of new immunotherapies.
- Advancements in protein design technology.
What Threats Does NLTX Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Difficulty in securing funding.
What Are NLTX's Competitive Advantages?
- Proprietary protein design technology platform.
- Novel de novo protein therapeutics.
- Patent protection for NL-201 and other product candidates.
- Expertise in protein engineering and immunology.
What Does NLTX Do?
Founded in 2003 and headquartered in Seattle, Washington, Neoleukin Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative immunotherapies. Originally named Aquinox Pharmaceuticals, Inc., the company rebranded in August 2019 to reflect its strategic shift towards protein design technology. Neoleukin's core focus lies in creating de novo proteins that mimic the therapeutic activity of naturally occurring cytokines, specifically interleukin (IL)-2 and IL-15. Their lead product candidate, NL-201, is designed to treat various cancers, including renal cell carcinoma and melanoma, by stimulating the body's immune system to target and destroy cancer cells. This novel approach aims to provide more effective and less toxic cancer treatments compared to traditional therapies. Neoleukin's research and development efforts are centered on leveraging its protein design platform to expand its pipeline of immunotherapeutic candidates for cancer, inflammation, and autoimmune diseases. The company's strategy involves preclinical and clinical development programs to advance its product candidates through regulatory approval and ultimately commercialization.
What Products and Services Does NLTX Offer?
- Develops immunotherapies for cancer.
- Utilizes protein design technology to create novel therapeutics.
- Focuses on creating de novo proteins that mimic the activity of cytokines.
- Lead product candidate is NL-201, targeting renal cell carcinoma and melanoma.
- Aims to provide more effective and less toxic cancer treatments.
- Conducts preclinical and clinical development programs.
How Does NLTX Make Money?
- Develops and patents novel protein therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Potentially partners with larger pharmaceutical companies for commercialization.
What Industry Does NLTX Operate In?
Neoleukin Therapeutics operates within the competitive and rapidly evolving biopharmaceutical industry, specifically in the area of specialty and generic drug manufacturing. The industry is characterized by intense research and development, stringent regulatory requirements, and high levels of competition. Companies like Neoleukin are striving to develop novel therapies for cancer and other diseases, driven by increasing global healthcare expenditure and unmet medical needs. The market for cancer immunotherapies is experiencing significant growth, with projections estimating substantial expansion in the coming years. Neoleukin's success depends on its ability to differentiate its products through innovative protein design and demonstrate clinical efficacy.
Who Are NLTX's Key Customers?
- Patients with cancer, inflammation, and autoimmune disorders.
- Healthcare providers who prescribe and administer immunotherapies.
- Pharmaceutical companies interested in licensing or acquiring novel therapeutics.
Company Profile
Neoleukin Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Donna M. Cochener-Metcalfe. NLTX has traded publicly since 2014.
F-Score 2/9Financial Health
Neoleukin Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.35 places it in the distress zone, a signal of elevated financial risk.
ROE -38%Key Financial Metrics
Return on equity for Neoleukin Therapeutics, Inc. stands at -37.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.5%, showing how much profit it generates from its asset base. A current ratio of 13.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -126.7%, the inverse of the P/E and a quick read on earnings relative to price.
NLTX Valuation & Market Position
With a $8.20M market cap, Neoleukin Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NLTX's quantitative score of 52/100 is below the peer average of 66/100.
Net buyingInsider Activity
The most recent 11 insider filings for Neoleukin Therapeutics, Inc. break down as 5 sales and 6 purchases. On net that is roughly 46K shares acquired (about $3.6M) — insiders putting money in tends to read as conviction.
NLTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Neoleukin's pipeline and future prospects, indicating that leadership sees potential for growth.
- Community sentiment has turned increasingly positive, with discussions highlighting the innovative nature of Neoleukin's therapeutic approach.
- Recent announcements about collaborations and partnerships have sparked interest, positioning the company well within the biotech sector.
- Analysts have noted the increasing relevance of Neoleukin's technology in addressing unmet medical needs, which could enhance its market appeal.
Bear Case
- Concerns about the competitive landscape in the biotech sector have emerged, as many companies vie for attention with similar therapeutic solutions.
- Recent social media sentiment has shown skepticism regarding the timeline for clinical results, leading to uncertainty among investors.
- Insider selling activity has raised red flags for some, suggesting that not all leadership is fully confident in the near-term outlook.
- Market perception remains cautious due to the inherent risks associated with biotech investments, particularly in early-stage companies like Neoleukin.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
NLTX Latest News
No recent news available for NLTX.
NLTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NLTX.
Price Targets
Wall Street price target analysis for NLTX.
NLTX MoonshotScore
What does this score mean?
The MoonshotScore rates NLTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Donna M. Cochener-Metcalfe
Unknown
Information about Donna M. Cochener-Metcalfe's background is not available in the provided data. Therefore, it is not possible to provide details about her career history, education, or previous roles.
Track Record: Information about Donna M. Cochener-Metcalfe's track record is not available in the provided data. Therefore, it is not possible to provide details about her key achievements, strategic decisions, or company milestones under her leadership.
NLTX Healthcare Stock FAQ
What does Neoleukin Therapeutics, Inc. do?
Neoleukin Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer, inflammation, and autoimmunity. The company utilizes its proprietary protein design technology to create novel de novo proteins that mimic the therapeutic activity of naturally occurring cytokines. Their lead product candidate, NL-201, targets cancer by mimicking the activity of interleukin cytokines, aiming to provide more effective and less toxic cancer treatments. Neoleukin's strategy involves preclinical and clinical development programs to advance its product candidates through regulatory approval and ultimately commercialization.
What do analysts say about NLTX stock?
Analyst coverage of Neoleukin Therapeutics, Inc. (NLTX) is limited, reflecting its small market capitalization and early stage of development. Consensus estimates regarding future revenue and earnings growth are not widely available. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's current lack of profitability. Investors should carefully consider the company's financial position, clinical trial results, and regulatory prospects when evaluating NLTX. The company's success hinges on positive clinical data and strategic partnerships.
What are the main risks for NLTX?
Neoleukin Therapeutics, Inc. faces several significant risks inherent to the biopharmaceutical industry. Clinical trial failures for NL-201 represent a major risk, as negative results could halt the company's development program. Regulatory hurdles in obtaining approval for NL-201 also pose a threat, as the FDA review process is rigorous and uncertain. Competition from larger pharmaceutical companies with more resources could limit Neoleukin's market share. Furthermore, the company's limited financial resources and small number of employees create ongoing risks related to funding and operational capacity.
What are the key factors to evaluate for NLTX?
Neoleukin Therapeutics, Inc. (NLTX) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does NLTX data refresh on this page?
NLTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NLTX's recent stock price performance?
Neoleukin Therapeutics, Inc. (NLTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative protein design technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NLTX overvalued or undervalued right now?
Valuing Neoleukin Therapeutics, Inc. (NLTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NLTX?
Before investing in Neoleukin Therapeutics, Inc. (NLTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- Future clinical trial results are uncertain.
- Market conditions and competition may impact results.